Is It Ethical to Use Placebos in Osteoporosis Trials?

Journal of Clinical Densitometry

Volumn 9, Issue 3, 2006, Pages 274-280

  Ragi Eis, Sergio ^a   Zerbini, Cristiano A F ^b   Provenza, José R ^c   Griz, Luiz H M ^d   de Gregório, Luiz H ^e   Russo, Luis A T ^e   Silva, Nilzio A ^f   Borges, João L C ^g   de Souza, Antonio C A ^h   Castro, Marize L ⁱ   Lewiecki, E Michael ^j  

^a CEDOES   (Brazil)

^b HOSPITAL HELIÓPOLIS   (Brazil)

^c PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^e Center for Clinical Research   (Brazil)

^f FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^g UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^h PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

ⁱ FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^j NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

more..

Author keywords

Clinical trials; control; drug studies; ethics; fracture; osteoporosis; placebo

Indexed keywords

CALCIUM; PLACEBO; VITAMIN D;

ARTICLE; DRUG RESEARCH; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; FRACTURE; HEALTH CARE COST; HIGH RISK PATIENT; MEDICAL ETHICS; MEDICAL RESEARCH; METHODOLOGY; OSTEOPOROSIS; PRIORITY JOURNAL; REGISTRATION; RISK REDUCTION; SAMPLE SIZE; SCIENTIST; STATISTICAL ANALYSIS;

CALCIUM, DIETARY; CONTROLLED CLINICAL TRIALS; CONTROLLED CLINICAL TRIALS AS TOPIC; FRACTURES, BONE; HUMANS; INFORMED CONSENT; META-ANALYSIS; META-ANALYSIS AS TOPIC; OSTEOPOROSIS; PATIENT RIGHTS; PLACEBOS; SAFETY; VITAMIN D;

EID: 33747376445     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2006.04.001     Document Type: Article

References (33)

1. World Medical Association (http://www.wma.net/e/policy/b3.htm).
2. Epstein S., Cryer B., Ragi S., et al. Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res and Opinion 19 8 (2003) 781-789
3. Oguz N.Y. Research ethics committees in developing countries and informed consent: with special reference to Turkey. J Lab Clin Med 141 (2003) 292-296
4. Wang V., and Marsh F. Ethical principles and cultural integrity in health care delivery: Asian ethnocultural perspectives in genetic services. J Genet Couns 1 (1992) 81-92
5. Levine R.J. The need to revise the Declaration of Helsinki. N Eng J Med 341 (1999) 531-534
6. Levine R.J. Placebo controls in clinical trials of new therapies for osteoporosis. J Bone Miner Res 18 6 (2003) 1154-1159
7. Lindsay R. Estrogens, bone mass and osteoporotic fracture. Am J Med (1991) 25;91(5B):10S-13S
8. Riggs B.L., Hodgson S.F., O'Fallon W.M., et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med (1990) 22;322(12):802-809
9. Rico H. Calcitonin and treatment of osteoporosis. J Med 16 4 (1985) 493-495
10. Kleerekoper M. Fluoride and the skeleton. Crit Rev Clin Lab Sci 33 2 (1996) 139-161
11. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., and Allan J.D. Postmenopausal hormone replacement therapy: scientific review. JAMA 288 7 (2002) 872-881
12. Guidelines for the preclinical and clinical evaluation of agents used in the prevention of treatment of postmenopausal osteoporosis (http://www.fda.gov/ohrms/dockets/dockets/98p0311/Tab0026.pdf).
13. Chapuy M.C., Arlot M.E., Duboeuf F., et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med (1992) 3;327(23):1637-1642
14. Emanuel E.J., and Miller F.G. The ethics of placebo-controlled trials-a middle ground. N Engl J Med (2001) 20;345(12):915-919
15. Freedman B., Glass K.C., and Weijer C. Placebo orthodoxy in clinical research. II: ethical, legal, and regulatory myths. J Law Med Ethics 24 3 (1996) 252-259
16. Siris E.S., Miller P.D., Barrett-Connor E., et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA (2001) 12;286(22):2815-2822
17. International Osteoporosis Foundation (http://www.osteofound.org).
18. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA (2002) 17;288(3):321-333
19. Gorelick K.J., Marcus D.M., Cohen F.J., and Jenny-Avital E.R. What ails the FDA?. N Engl J Med 352 (2005) 2553-2555
20. Grocott R., and Metcalfe S. Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. N Z Med J (2005) 7;118(1223):U1690
21. Dawson-Hughes B., Harris S.S., Krall E.A., and Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med (1997) 4;337(10):670-676
22. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., Giovannucci E., Dietrich T., and Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293 (2005) 2257-2264
23. Dawson-Hughes B., Heaney R.P., Holick M.F., Lips P., Meunier P.J., and Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 16 7 (2005) 713-716
24. Papadimitropoulos E., Wells G., Shea B., et al., the Osteoporosis Methodology Group, The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. [Review]. Endocr Rev 23 4 (2002) 560-569
25. Larsen E.R., Mosekilde L., and Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 19 3 (2004) 370-378
26. Grant A.M., Avenell A., Campbell M.K., et al., the RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people: a randomised placebo-controlled trial. Lancet (2005) 365(9471):1621-1629
27. Porthouse J., Cockayne S., King C., et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ (2005) 30;330(7498):1003
28. (2001), LLC and PhRMA, Washington Analysis
29. Lips P, Chandler J, Lippuner K, et al. High prevalence of vitamin D inadequacy among community dwelling post-menopausal women with osteoporosis. Abstract presented at ASBMR, Nashville, TN, September 23-27, 2005.
30. Gallacher S.J., McQuillian C., Harkness M., et al. Prevalence of vitamin D inadequacy in Scottish adults with non-vertebral fragility fractures. Curr Med Res Opinion 21 9 (2005) 1355-1361
31. Jackson R.D., LaCroix A.Z., Gass M., et al., the Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 16;354(7):669-683
32. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, and The Osteoporosis Methodology Group, The Osteoporosis Research Advisory Group, 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23(4):570-578.
33. Heaney R.P. Ethical issues in the design of osteoporosis clinical trials: the state of the question. J Bone Min Res 18 6 (2003) 1117-1120